COMBINATION THERAPY OF ANTI-PD-1 ACTIVE AGENT, ANTI-TIM-3 ACTIVE AGENT, AND ANTI-LAG-3 ACTIVE AGENT FOR TREATING CANCER

The present disclosure provides a combination therapy which comprises: (i) an active agent that binds PD-1 (e.g., an anti-PD-1 antibody), (ii) an active agent that binds TIM-3 (e.g., an anti-TIM-3 antibody), and/or (iii) an active agent that binds LAG-3 (e.g., an anti-LAG-3 antibody). The present disclosure provides pharmaceutical compositions thereof, uses thereof, and methods of treatment which include administering the combination therapy to a subject, including methods of treating cancer. La présente invention concerne une polythérapie qui comprend : (i) un agent actif qui se lie à PD-1 (par ex. , un anticorps anti-PD-1), (ii) un agent actif qui se lie à TIM-3 (par ex. , un anticorps anti-TIM-3), et/ou (iii) un agent actif qui se lie à LAG-3 (par ex. , un anticorps anti-LAG-3). La présente invention concerne des compositions pharmaceutiques associées, leurs utilisations, et des méthodes de traitement qui comprennent l'administration de la polythérapie à un sujet, notamment des méthodes de traitement du cancer.